2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2015 Featured Talks » Advancing the Utility of Clinic Sequencing for MDS



Advancing the Utility of Clinic Sequencing for MDS

Rafael Bejar, MD, PhD
UC San Diego Moores Cancer Center





Rafael Bejar, MD, PhD
Assistant Professor, Division of Hematology Oncology
UC San Diego Moores Cancer Center


Dr. Rafael Bejar is a physician-scientist at the UCSD Moores Cancer in La Jolla, California where his laboratory studies the molecular basis of myelodysplastic syndromes (MDS) and related neoplasms. He obtained his medical and PhD degrees in the Medical Scientist Training Program at UCSD prior to his medical internship at the University of Chicago. He completed his residency in Internal Medicine at the Brigham and Women’s Hospital in Boston where he later served as a Chief Medical Resident. He then served as fellow in Hematology and Oncology at the Dana-Farber Cancer Institute where he later became an Instructor. There he worked in laboratory of Dr. Benjamin Ebert on the genetic basis of MDS.

In collaboration with several groups, Dr. Bejar’s work has helped identify how genetic mutations contribute to the development of MDS and how testing for these abnormalities can help physicians care for their patients with this disease (New England Journal of Medicine, 2011). Most recently, he has published on mutations that predict response to treatment with hypomethylating agents (Blood, 2014) and outcomes after stem cell transplantation (Journal of Clinical Oncology, 2014). His laboratory is now focused on the role of somatic mutations in splicing factors and epigenetic regulators in MDS.

Dr. Bejar serves on the molecular prognosis committee of the International Working Group for MDS and is a member of the NCCN clinic guidelines committee for MDS. At UCSD, Dr. Bejar has established an MDS Center of Excellence where he cares for patients, oversees clinical trials, and continues to study the molecular mechanisms that drive the development of MDS.